Compare Church & Dwight Co., Inc. (CHD) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Church & Dwight Co., Inc. vs Inovio Pharmaceuticals Inc — how do they compare? Church & Dwight Co., Inc. trades at $96.64 (market cap $22.61B), while Inovio Pharmaceuticals Inc trades at $1.17 (market cap $95.85M). The key difference: Church & Dwight Co., Inc. is far larger — about 235.9× Inovio Pharmaceuticals Inc's market cap, and Church & Dwight Co., Inc. pays a 1.29% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CHD | INO | |
|---|---|---|
Market Cap | $22.61B | $95.85M |
Sector | Consumer Staples | Health |
52-Week High | $105.26 | $2.87 |
52-Week Low | $81.60 | $1.05 |
Enterprise Value | $24.31B | $66.86M |
Dividend Yield | 1.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Church & Dwight (CHD) trades at $97.16, up 0.83% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with 11.81% net margins and consistent organic growth, supported by strategic acquisitions like Miss Mouth's brand. Analyst consensus remains positive with a $105.60 price target, though cash flow trends show recent negative net flows.
CHD presents a balanced opportunity with solid brand execution and margin expansion potential, offset by cash flow volatility and competitive pressures. The stock's premium valuation requires sustained earnings growth to justify upside, with Q2 2026 earnings on July 31 as a key catalyst.
INO trades at $1.16, down 1.69% on the day, with a bearish technical outlook from moving averages. The company shows minimal revenue of $65.34K in 2025 and a net loss of $84.95M, resulting in a negative net margin of 130,000%. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation concerns.
The investment case hinges on the binary FDA decision for INO-3107, offering high upside potential but significant risk. Analyst consensus is moderately positive with 53% buy ratings, yet fundamental weaknesses and negative cash flows pose substantial risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
